Skip to main content
Caffeine is a proconvulsant in animal models at high doses, and case reports link caffeine intake to increased seizure frequency in individual patients. Decaf’s 2 to 15 mg residual caffeine is 13 to 200 times below the lowest dose associated with proconvulsant effects in human-relevant research.

How Caffeine Affects Seizure Threshold

Caffeine antagonizes adenosine A1 receptors in the brain. Adenosine A1 receptor activation normally inhibits neuronal firing. Blocking this inhibition lowers the threshold for neuronal excitation and can increase susceptibility to seizure activity. Animal model research has documented caffeine’s proconvulsant effect at specific doses. At 5 mg/kg and 50 mg/kg in rodents, caffeine increased seizure susceptibility via adenosine A1 receptor blockade and disruption of nitric oxide and cyclic GMP signaling. At 100 mg/kg, the proconvulsant effect paradoxically diminished in some models, suggesting a non-linear dose response. These doses do not translate directly to human thresholds, but they establish a plausible biological mechanism. Caffeine may also reduce the efficacy of anti-epileptic drugs. A 2022 study by Chwedorowicz et al. found pharmacodynamic interactions between caffeine and levetiracetam (Keppra), one of the most widely prescribed anti-epileptic drugs, with caffeine attenuating the drug’s anticonvulsant effect in animal models. A 2019 study by Phillips et al. found that caffeine exacerbated postictal hypoxia (reduced oxygen to the brain following a seizure), which is a separate risk from the seizure itself.

Clinical and Epidemiological Evidence

Human data is more equivocal than animal model data. A study by Samsonsen et al. (2016) followed 179 hospital admissions for seizures and compared caffeine intake on the day of seizure versus matched control days. Caffeine was not significantly more prevalent on seizure days than control days. Sleep loss was the dominant precipitant, not caffeine. An American Epilepsy Society (AES) meeting abstract concluded that caffeine “does not appear to be a common seizure precipitant” in the general epileptic population, while acknowledging it may be a factor for individual patients. A case report published in Seizure (2003) by Kaufman and Sachdeo (PMID 12967583) documented a patient whose seizure frequency increased with caffeinated tea consumption. When switched to decaffeinated tea, seizure frequency returned to baseline. Re-introduction of caffeinated tea caused relapse. This is an n=1 case and cannot be generalized, but it illustrates that caffeine-sensitive individuals exist within the epileptic population.

What Changes with Decaf

A standard cup of caffeinated coffee contains 80 to 200 mg of caffeine. Decaf processed via the Swiss Water® Process contains 2 to 15 mg per serving. The lowest dose associated with proconvulsant effects in animal models, when scaled to human body weight, produces a threshold far above the residual caffeine in a cup of decaf. The 13 to 200-fold margin between decaf’s residual caffeine (2 to 15 mg) and any documented seizure-relevant threshold does not make decaf zero risk for every individual, but it substantially reduces the pharmacological basis for concern compared to regular coffee. Decaf also eliminates the caffeine-mediated levetiracetam interaction documented by Chwedorowicz et al. People on anti-epileptic drug regimens who switch to decaf reduce this pharmacodynamic interference.

Individual Sensitivity Varies

Epilepsy encompasses a broad range of syndromes with different etiologies, seizure types, and trigger profiles. What precipitates seizures in one patient may be irrelevant in another. Caffeine sensitivity as a seizure trigger is documented primarily in case reports and small observational studies, not in controlled trials with defined effect sizes. People with epilepsy whose seizure frequency correlates with their coffee intake, or whose neurologist has advised caffeine restriction, are the primary group for whom even decaf’s residual 2 to 15 mg may warrant discussion with a clinician.

What Colipse Coffee offers for people with seizure disorders

How each product relates to seizure management

Half Caff provides a measurable step-down from regular coffee for people whose epileptologist has advised reducing caffeine rather than eliminating it. The Samsonsen 2016 study found caffeine was not a common seizure precipitant across the epileptic population - the clinical picture is individual. For people who have not identified caffeine as a personal trigger but want to reduce their intake as a precaution, Half Caff halves the caffeine load while preserving the coffee ritual that supports the consistent sleep schedule that Samsonsen identified as the more critical variable. Dark Roast Decaf eliminates the caffeine-driven mechanisms relevant to seizure risk: adenosine A1 receptor disinhibition documented in animal proconvulsant models, and the pharmacodynamic interference with levetiracetam found by Chwedorowicz et al. (2022). Residual caffeine of 2 to 15 mg per cup is 13 to 200 times below any dose associated with proconvulsant effects in the research. For people on anti-epileptic medication with narrow therapeutic windows, removing caffeine as a competing metabolic variable simplifies drug management.

Frequently Asked Questions

For most people with epilepsy, decaf coffee’s 2 to 15 mg of residual caffeine is unlikely to affect seizure threshold. Population-level evidence (Samsonsen 2016, AES abstract) found caffeine is not a common seizure precipitant across the epileptic population. Individual caffeine sensitivity varies, and case reports document patients whose seizure frequency is responsive to caffeine intake. Anyone with seizures that appear correlated with coffee or caffeine consumption should discuss it with their neurologist before switching to decaf rather than assuming decaf is safe.
A 2022 study by Chwedorowicz et al. found that caffeine reduced the anticonvulsant efficacy of levetiracetam (Keppra) in animal models. Other anti-epileptic drugs have different metabolic pathways; the interaction is not universal across all medications. Decaf’s 2 to 15 mg residual caffeine substantially reduces but does not eliminate the pharmacodynamic interaction for levetiracetam-sensitive individuals. Anyone adjusting caffeine intake while on anti-epileptic medication should discuss it with their prescribing neurologist.
Yes, according to the available evidence. The Samsonsen 2016 study found sleep loss was the dominant precipitant in 179 hospital admissions for seizures, not caffeine intake. This does not mean caffeine is irrelevant for all individuals, but it contextualizes caffeine as a lower-priority trigger for most people with epilepsy compared to sleep disruption. Caffeine at high doses that disrupt sleep may indirectly increase seizure risk through sleep deprivation rather than through its direct proconvulsant mechanism.

Disclaimer

This page is for educational purposes only and does not constitute medical advice. If you have epilepsy or a seizure disorder, consult your neurologist or epileptologist before making changes to your caffeine intake, particularly if you are taking anti-epileptic medication.